Clinical Trial Update: A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the renal protective effect of ipragliflozin in patients with Type 2 diabetes mellitus and albuminuria was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ipragliflozin (ipragliflozin)

Snippet

Sponsor: Astellas Pharma Korea, Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: TERMINATED